000			01759 a2200457 4500
005			20250514002227.0
264		0	_c20011025
008			200110s 0 0 eng d
022			_a0733-8651
024	7		_a10.1016/s0733-8651(05)70210-1 _2doi
040			_aNLM _beng _cNLM
100	1		_aVernon, S M
245	0	0	_aGlycoprotein IIb/IIIa antagonists and low-molecular weight heparin in acute coronary syndromes. _h[electronic resource]
260			_bCardiology clinics _cMay 2001
300			_a235-52, vi p. _bdigital
500			_aPublication Type: Journal Article; Review
650	0	4	_aAbciximab
650	0	4	_aAngina, Unstable _xdrug therapy
650	0	4	_aAntibodies, Monoclonal _xadverse effects
650	0	4	_aCoronary Artery Bypass
650	0	4	_aDalteparin _xtherapeutic use
650	0	4	_aEnoxaparin _xtherapeutic use
650	0	4	_aEptifibatide
650	0	4	_aFibrinolytic Agents _xtherapeutic use
650	0	4	_aHemorrhage _xchemically induced
650	0	4	_aHeparin, Low-Molecular-Weight _xadverse effects
650	0	4	_aHumans
650	0	4	_aImmunoglobulin Fab Fragments _xadverse effects
650	0	4	_aMyocardial Infarction _xdrug therapy
650	0	4	_aNadroparin _xtherapeutic use
650	0	4	_aPeptides _xadverse effects
650	0	4	_aPlatelet Aggregation Inhibitors _xtherapeutic use
650	0	4	_aPlatelet Glycoprotein GPIIb-IIIa Complex _xadverse effects
650	0	4	_aThrombocytopenia _xchemically induced
650	0	4	_aThrombosis _xchemically induced
650	0	4	_aTirofiban
650	0	4	_aTransaminases _xblood
650	0	4	_aTyrosine _xadverse effects
773	0		_tCardiology clinics _gvol. 19 _gno. 2 _gp. 235-52, vi
856	4	0	_uhttps://doi.org/10.1016/s0733-8651(05)70210-1 _zAvailable from publisher's website
999			_c11337364 _d11337364